NK Cell Adoptive Transfer for Inflammatory and Autoimmune Conditions

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammation, auto-immunity, and aging-related diseases are inadequate and lack comprehensive solutions, with each condition being individually targeted without a systemic approach, leading to partially overlapping therapeutic approaches that do not effectively address the underlying immune system mechanisms.

Innovation Solution

The use of CD3 negative and CD56 positive NK cells for adoptive transfer therapy, which involves isolating NK cells from peripheral blood, freezing, and reinfusing them to treat a range of conditions including cancer, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, thyroid autoimmune disease, psoriasis, and inflammatory bowel disease, aiming to regulate cytokine levels and reduce inflammation and senescence markers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If individual disease conditions are targeted separately with different therapeutic approaches, then each specific condition can be addressed, but the treatment approach becomes fragmented and does not effectively address underlying immune system mechanisms

Engineering Contradiction:

Improvedisease coverageVSAvoidtreatment approach complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies universality by using NK cells as a single therapeutic agent that can treat multiple different diseases (cancer, autoimmune diseases, inflammatory conditions, aging-related diseases) through a single adoptive transfer protocol, eliminating the need for different treatments for each condition while addressing underlying immune system mechanisms

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If conventional treatments are used for inflammatory and autoimmune diseases, then symptomatic relief can be achieved, but the underlying immune system mechanisms and root causes are not effectively addressed

Engineering Contradiction:

Improvesymptomatic reliefVSAvoidtreatment effectiveness

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies extraction by isolating and removing dysfunctional immune cells (through selective depletion or suppression) and replacing them with functional NK cells that can restore proper immune function, thereby addressing both symptoms and underlying immune system mechanisms simultaneously

Inventive Principle:

Principle #2Taking out (Extraction)

3Adaptability or versatility

If multiple separate therapies are administered for different disease conditions, then comprehensive coverage is achieved, but treatment duration and patient burden increase

Engineering Contradiction:

Improvedisease coverageVSAvoidtreatment duration

Core Design Contradiction:

Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent merges multiple separate therapies into a single adoptive transfer treatment that can address multiple disease conditions simultaneously, reducing treatment duration and patient burden while maintaining comprehensive disease coverage through the multi-functional NK cell therapy

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20230018682A1Methods and compositions of natural killer cell adoptive transfer therapy

Publication Date: 2023.01.19 RESTEM LLC

AI summary

Disclosed are methods and compositions useful for treating patients with inflammatory, auto-immune and age related conditions. The disclosure relates to using Natural Killer cells and derivatives thereof in order to induce therapeutic benefit to patients affected by disease and conditions such as cancer, multiple sclerosis, rheumatoid arthritis, type I diabetes mellitus, thyroid autoimmune disease, psoriasis and inflammatory bowel diseases.